MarketPulse

anti-IgE therapy

2 articles
BenzingaBenzinga··Vandana Singh

Novartis Doubles Down on Allergies With $2B Excellergy Acquisition

Novartis acquires Excellergy for up to $2 billion to develop Exl-111, a next-generation anti-IgE allergy drug in Phase 1 trials, strengthening its immunology pipeline.
NVSacquisitionbiotech
BenzingaBenzinga··Na

Novartis to Acquire Excellergy for Up to $2B, Bolstering Anti-IgE Allergy Portfolio

Novartis to acquire private biotech Excellergy for up to $2B, adding next-generation anti-IgE antibody Exl-111 targeting food allergy, chronic urticaria, and allergic asthma.
NVSacquisitionbiotech